Overview
- Highlights recent updates in immunotherapeutic strategies to treat patients with solid tumors
- Informs on the spectrum of immune-related adverse events
- Outlines strategies to overcome challenges associated with immunotherapies: atypical immune response and immune-related adverse events
- Acknowledges the importance of collecting and disseminating the missing patients’ voice and translational research
Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 1244)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (20 chapters)
-
Front Matter
Keywords
About this book
Immunotherapy is a rapidly evolving field that mandates frequent revision of the book as new insights to fight cancer emerge. The third edition of Immunotherapy is an updated overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. It explores the breath of immunotherapeutic strategies available to treat a wide range of cancers, from melanoma and non-small cell lung cancer to gastrointestinal, genitourinary, gynecologic and nervous system malignancies. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the challenges associated with their use undoubtedly increase. As objective response is limited to a subset of patients and is often associated with distinct immune related side effects that are potentially life threatening, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. In the absence of a validated predictive biomarker, innovative technologies and assays are being used to identify critical biomarkers that drive the immune response. Hence, a chapter to provide a basic understanding of the diagnostic procedures has been included besides the chapter on the cellular components of the human immune system. This new edition will also inform readers on use of novel microbiome and imaging approaches. Finally, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies as the authors recognize the importance of including missing patient voice in clinical trials and longitudinal assessment of symptom reports. In short, the third edition of this book provides a comprehensive overview of the latest developments in the field of immune-oncology that will help health care professionals make informed treatment decisions.
The book’s chapters are written by a diverse cast of experts conducting cutting-edge research,providing the reader with the most up-to-date science.
Editors and Affiliations
About the editors
Dr. Joud Hajjar is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Children’s Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology, and the Early Career Immunologist Committee at the Clinical Immunology Society. Dr. Hajjar's research interests are in primary immunodeficiency disorders, and cancer immunotherapy.
Bibliographic Information
Book Title: Immunotherapy
Editors: Aung Naing, Joud Hajjar
Series Title: Advances in Experimental Medicine and Biology
DOI: https://doi.org/10.1007/978-3-030-41008-7
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2020
eBook ISBN: 978-3-030-41008-7Published: 16 April 2020
Series ISSN: 0065-2598
Series E-ISSN: 2214-8019
Edition Number: 3
Number of Pages: XII, 339
Number of Illustrations: 9 b/w illustrations, 35 illustrations in colour
Topics: Cancer Research, Immunology, Oncology